Streetbeat News

Products Services

AMD

INTC

Intel has lost the contract for the next-generation Sony PlayStation chips to AMD, which is expected to generate over $30 billion in revenue for AMD over approximately five years.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:10 am

DRMA

NCNA

RFL

XCUR

Exicure, Inc. (NASDAQ:XCUR) shares surged over 49% in pre-market trading after the company entered into debt-for-equity exchange agreements and regained Nasdaq compliance. Other notable pre-market movers include NuCana plc (NASDAQ:NCNA) with a 94.4% gain due to positive Phase 2 study data, and Dermata Therapeutics, Inc. (NASDAQ:DRMA) rising 73.4%. On the downside, Rafael Holdings, Inc. (NYSE:RFL) fell 40.1% after previous gains.

Portfolio Pulse from Avi Kapoor

September 16, 2024 | 10:07 am

MIGI

Mawson Infrastructure Group Inc. (NASDAQ:MIGI) reported a 27% month-on-month revenue growth in August 2024, reaching $4.44 million. The company is expanding into AI and HPC colocation markets, signing a significant 6-year AI customer colocation agreement. Mawson's expansion into Ohio and Pennsylvania enhances its presence in the PJM market, focusing on sustainable energy solutions.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:05 am

KBR

KBR has secured a $140 million task order to provide safety and engineering support for the U.S. Air Force at Hill Air Force Base. The contract involves research and analysis to enhance operational safety and engineering tasks for various Air Force systems.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:02 am

TIL

Instil Bio has announced a global registrational strategy for its PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, in combination with chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). The company plans to initiate Phase 1b/2 trials in China in late 2024 for NSCLC and early 2025 for TNBC. A US IND submission for SYN-2510 is targeted for late 2024, with a Phase 2 trial for second-line NSCLC.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 10:02 am

RIVN

TSLA

Tesla's Cybertruck significantly boosted EV registrations in the U.S. in July, with Tesla seeing a 1.2% increase in registrations. Despite heavy incentives driving sales, Tesla's dominance in the EV market remains strong, while Rivian saw a slight decline.

Portfolio Pulse from Anan Ashraf

September 16, 2024 | 9:57 am

BMY

IMTX

Immatics presented promising clinical data for its TCER IMA401 at the ESMO Congress, showing significant efficacy in various cancers. Immatics will regain full rights to IMA401 from Bristol Myers Squibb due to portfolio prioritization.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:31 am

ME

23andMe presented nonclinical data at the ESMO Congress showing the anti-tumor activity of its 23ME-01473 antibody, which targets the NKG2D ligand ULBP6. The antibody inhibited tumor growth in a mouse model of non-small cell lung cancer. Elevated ULBP6 levels were confirmed in certain carcinomas, suggesting potential clinical applications. A Phase 1 trial is ongoing, with the first patient dosed in March 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:27 am

INCY

Incyte announced successful results from its Phase 3 trial of retifanlimab combined with chemotherapy for treating squamous cell anal carcinoma. The trial met its primary endpoint, supporting a planned U.S. filing for a supplemental Biologics License Application by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:23 am

NTRA

Natera has announced the publication of three new peer-reviewed papers, bringing the total to over 85 publications on its cancer diagnostic test, Signatera. This milestone highlights the growing validation and acceptance of Signatera in the medical community.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 9:21 am